Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03603184
Title Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Mario Negri Institute for Pharmacological Research
Indications

endometrial carcinoma

uterine carcinosarcoma

Therapies

Atezolizumab + Carboplatin + Paclitaxel

Carboplatin + Paclitaxel

Age Groups: adult | senior
Covered Countries ITA | ESP | DEU | AUT


No variant requirements are available.